Search Results
Austin, S. K., Lambert, J. R.: The JAK2 V617F mutation and thrombosis. Br. J. Haematol., 2008, 143 , 307–320. Lambert J. R
Diagnosztikus és terápiás dilemmák polycythaemia verában
Diagnostic and therapeutic dilemmas in polycythaemia vera
. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013; 369: 2391–2405. 7 Chittiboina P, Lonser RR. Von Hippel–Lindau disease. Handb Clin
., et al.: Condotional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood, 2010, 115 (17), 3589
–103. [Hungarian] 10 Tefferi, A.: Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF
2185 2193 Passamonti, F., Rumi, E., Pietra, D., et al.: JAK2 (V617F) mutation in healthy individuals. Br. J. Haematol., 2007, 136 , 677
; 109: 2446–2452. 10 Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb
Haemostasis Research (GTH e.V.). Ann. Hematol., 2014, 93 (12), 1953–1963. 25 Pósfai, É., Marton, I., Király, P. A., et al.: JAK2 V617F, MPL, and CALR mutations in
Antonioli, E., Guglielmelli, P., Pancrazzi, A. és mtsai Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia, 2005, 19 , 1847
.: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 2005, 365 (9464), 1054–1061. James, C., Ugo, V., Le Couédic, J. P., et al.: A unique clonal JAK2 mutation leading to
Két myeloproliferativ betegség egy betegben – klónok együttélése és vetélkedése
Two myeloproliferative diseases in one patient – co-occurence of clones
–375. 2 Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849 G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood
